A Return to Normal
The body’s defense against pathogens requires proper immune function which depends on two major pillars: the innate immune system, operating as the first line of defense against pathogens, and the adaptive immune system, which generates cellular and humoral defenses against specific antigens. In a healthy immune system, these complex networks of cells, organs and tissues work together in harmony. However, when one or more components goes awry, the result can be a wide range of inflammatory and autoimmune diseases that can be debilitating and life-threatening, affecting millions of people worldwide.
Q32 Bio’s therapeutic approach targets endogenous regulators of both the innate and adaptive immune systems and is focused on restoring immune homeostasis. We are currently advancing two programs – a portfolio of therapeutic fusion proteins that deliver powerful negative regulators of complement activation directly to disease-affected tissues; and a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R) that potently modulates T cell function.
Restoring Innate Immunity:
Key to innate immunity is the complement system, a first line of defense for fighting pathogens and clearing apoptotic cells. However, when hyperactivated, it is a driver of a variety of autoimmune and inflammatory diseases in which the complement system attacks and damages healthy tissues. Many current therapeutic approaches target complement systemically, increasing the risk of serious infections and other complications. Q32 Bio is designing molecules that provide potent regulation of complement in diseased tissues without long-term systemic blockade – a key differentiator versus current complement therapeutics. Our lead complement fusion protein is called ADX-097.Complement Program
Restoring Adaptive Immunity:
Activation of IL-7R can drive several T cell-mediated pathological processes. It lowers the threshold-response to disease-related antigens by stimulating T-effector and T-memory cells and inhibits the immunosuppressive function of T-regulatory cells. As a result, IL-7R signaling can induce T-effector cell pathology, abherrant regulatory T cell suppression, and T cell-dependent autoantibody responses. Inhibition of IL-7R signaling has the potential to durably and safely restore healthy immune regulation in numerous autoimmune and inflammatory diseases. Q32 Bio is developing a fully human anti-IL-7R antibody, ADX-914, that re-regulates adaptive immune function.IL-7R Program